For decades, KRAS was considered undruggable. The protein’s smooth surface offered no obvious pocket for a drug to grab. Then researchers found a shallow groove near one specific mutation — G12C — and designed molecules that slip into it. These drugs, called KRAS G12C inhibitors, lock the mutant protein in its inactive state and slow the signals that tell cancer cells to keep dividing.
How Do KRAS Inhibitors Target the G12C Mutation?
The G12C mutation swaps one amino acid — glycine becomes cysteine — at position 12 of the KRAS protein. That single change creates a reactive sulfur-containing group on the protein’s surface.
KRAS G12C inhibitors like sotorasib and adagrasib contain a chemical group that forms a covalent bond with that cysteine. This is not a loose, reversible interaction. It is a permanent chemical tether. Once the drug binds, the KRAS protein is locked into its inactive, GDP-bound form.
The result is straightforward: the mutant protein cannot send growth signals. The downstream pathway — RAF, MEK, ERK — quiets down. Cancer cells that depend on this signal slow their division.
This mechanism is unusual. Most targeted cancer drugs block a protein’s active site or compete with ATP. KRAS G12C inhibitors work differently. They exploit a chemical feature that only the mutant protein has. Normal KRAS has glycine at position 12, not cysteine, so the drug does not bind normal KRAS. That selectivity is the whole point.
Why Was KRAS Considered Undruggable for So Long?
KRAS is a small protein with a smooth surface. It has no deep pockets where a drug can nestle. For years, researchers tried to design molecules that would block KRAS, and they failed.
The protein also binds GTP — its activating molecule — very tightly. Competing with GTP is difficult because GTP is present at high concentrations inside cells. Early attempts to block KRAS directly were not successful in clinical testing.
The breakthrough came when researchers at a pharmaceutical company noticed a pocket near the switch II region of KRAS G12C. This pocket is not present in the same way on other KRAS mutants. It was a narrow opening, but it was enough. The cysteine at position 12 sits near this pocket, and a drug can reach in and form a covalent bond.
This discovery changed the field. It showed that even a protein with no obvious drug-binding site can be targeted if you find the right chemical handle.
Which Cancers Have the KRAS G12C Mutation?
The G12C mutation appears most often in non-small cell lung cancer (NSCLC). About 13% of lung adenocarcinomas carry it. It is also found in colorectal cancer and, less commonly, in pancreatic cancer, uterine cancer, and some other solid tumors.
KRAS mutations overall are among the most common cancer-driving mutations. But G12C is a specific subtype. Not all KRAS mutations are G12C. G12D and G12V are more common in pancreatic and colorectal cancers, and drugs targeting those mutations are still in earlier stages of development.
This matters because a KRAS G12C inhibitor will not work for a tumor that has a different KRAS mutation. Testing the tumor’s DNA — usually from a biopsy or a blood sample — is necessary before using these drugs.
How Well Do KRAS G12C Inhibitors Work?
Sotorasib and adagrasib are approved by the FDA for previously treated KRAS G12C-mutated non-small cell lung cancer. They shrink tumors in a meaningful portion of patients, but not everyone responds.
In clinical trials, response rates have generally been in the range of roughly one-third to one-half of patients. That means many tumors do not shrink significantly. And even when they do, the response often does not last. Resistance develops, usually within months.
The reasons for resistance are varied. Cancer cells can activate other signaling pathways. They can acquire new mutations in KRAS itself. They can amplify the mutant gene. The tumor finds workarounds.
These drugs are not cures. They are options for patients who have already received other treatments, usually chemotherapy and immunotherapy. They offer a targeted approach where none existed before, but the benefit is temporary for most people.
Researchers are testing combinations — KRAS G12C inhibitors with other targeted drugs, with chemotherapy, with immunotherapy — to see if responses can be deeper and last longer. Some early results are encouraging, but the evidence is still maturing.
What Are the Limitations of Targeting G12C?
First, the mutation must be present. Only about 13% of lung adenocarcinomas have it. For other cancers, the percentage is lower. A patient without the mutation will not benefit.
Second, resistance is common. The tumor adapts. This is not unique to KRAS inhibitors — most targeted cancer drugs face the same problem — but it limits how long these drugs help.
Third, the drugs have side effects. Common ones include diarrhea, nausea, liver enzyme changes, and fatigue. Some patients experience more serious issues. These are not benign treatments.
Fourth, the G12C mutation is just one of many KRAS mutations. G12D, G12V, and others are more common in some cancers. Drugs for those mutations are in development, but they are not yet approved.
Finally, even within G12C-mutated tumors, not all cancers depend on KRAS for their growth. Some have other driving mutations that dominate. The biology is complex.
What Does the Future Hold for KRAS Targeting?
The success with G12C opened the door. Researchers are now working on drugs that target other KRAS mutations, including G12D and G12V. Some of these are in early clinical trials.
Another approach is to target KRAS indirectly — by blocking the proteins it interacts with, like SHP2 or SOS1. These are called indirect inhibitors, and they are being tested in combination with direct KRAS inhibitors.
There is also interest in pan-KRAS inhibitors — drugs that might work across multiple KRAS mutations. These are earlier in development.
The field is moving, but progress takes time. What works in a laboratory does not always work in people. Clinical trials are needed to prove benefit.
Frequently Asked Questions
What is the G12C mutation in KRAS?
It is a specific change in the KRAS gene where the amino acid glycine at position 12 is replaced by cysteine. This mutation makes the KRAS protein stay active and drive cancer cell growth.
How do KRAS G12C inhibitors work?
They bind to the cysteine created by the G12C mutation and lock the KRAS protein in its inactive state. This blocks the signals that tell cancer cells to divide.
Which cancers have the KRAS G12C mutation?
It is most common in non-small cell lung cancer, where it appears in about 13% of lung adenocarcinomas. It is also found in colorectal cancer and some other solid tumors, though less often.
Are KRAS G12C inhibitors a cure for cancer?
No. They can shrink tumors in some patients, but resistance usually develops and the response does not last. They are used as treatments, not cures.
Do KRAS G12C inhibitors work for all KRAS mutations?
No. They are designed specifically for the G12C mutation. Other KRAS mutations, like G12D or G12V, require different drugs that are still in development.
